New study aims to prevent heart rate spikes during breathing tube insertion
NCT ID NCT07089173
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests 99 adults having planned surgery to find the right remifentanil dose that keeps heart rate and blood pressure stable when a breathing tube is inserted. Patients receive either lidocaine, sufentanil, or a placebo alongside etomidate to see which combination works best. The goal is to improve safety during anesthesia induction.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
remifentanil, lidocaine, sufentanil, etomidate
What this could lead to
If successful, this could help anesthesiologists choose the safest drug combination to prevent dangerous heart rate spikes during intubation.
What could go wrong
This is a small, early-phase study (99 people) focused on a specific procedure, so results may not apply to all patients or surgeries. Side effects like low oxygen or muscle jerks are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMODYNAMICS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••